Bill Gates backs fusion and isotopes

Bill Gates-linked money showed up in two very different places this week — a cancer-drug isotope plant in Philadelphia and a fusion-power push in Britain. They look unrelated at first. But basically they target the same kind of problem: not flashy apps, but hard physical bottlenecks that hold back whole industries. One project broke ground on May 6. The other announced a consortium meant to build what its backers call the UK’s first private-sector-led fusion plant. ### What actually got built in Philadelphia? TerraPower Isotopes broke ground on a 250,000-square-foot manufacturing site in the Bellwether District in South Philadelphia. The project is priced at $450 million, and the company says commercial-grade actinium-225 production should begin in 2029. Pennsylvania helped land the plant with a $10 million package, and the state says the site will create at least 225 jobs. ### Why does actinium-225 matter? Actinium-225 is one of the rare isotopes used in targeted alpha therapies — cancer drugs that carry radioactive payloads straight to tumor cells. The promise is precision: hit the cancer hard, spare more healthy tissue. That is the kind of number that can change whether clinical programs stay niche or become real drug businesses. ### Why is supply the whole story here? A lot of cancer medicine progress gets framed as a biology problem. But for radiopharmaceuticals, manufacturing is often the rate limiter. If drug developers cannot get enough isotope, trials slow down and commercial launches get constrained. TerraPower is pitching this plant as a direct biotech programs reliably. ### What happened on the fusion side? Type One Energy, which counts Breakthrough Energy Ventures among its backers, said it has teamed up with Tokamak Energy and AECOM to form the UK Infinity Fusion Consortium. The group says it wants to deliver the UK’s first private-sector-led fusion plant. Its proposed machine uses Type One’s technology and AECOM’s construction experience. ### Why is that a big deal? Fusion has had no shortage of grand promises. What it has lacked is a believable path from physics demos to utility-scale projects. Type One is trying to sound different by talking less about scientific proof and more about deployable industrial systems. follow-on that can attract private capital. ### Why Britain, and why now? Because the UK is openly trying to turn fusion from a research specialty into an industry. In March, the government published a new fusion strategy and said it would back fusion research and commercialization with more than £2.5 billion over five years. — not just lab milestones. ### So what ties these two stories together? They are both infrastructure bets on scarcity. One scarce thing is actinium-225. The other is the stack of magnets, engineering, capital, and patience needed to make fusion commercial. Gates-linked investing has always had the decades. ### Bottom line? This week’s news is not that Bill Gates discovered two new moonshots. It is that two Gates-backed ecosystems moved a step closer to real-world deployment — one in cancer medicine, one in energy. That is slower money, heavier engineering, and a much longer clock. But turns out that is exactly the point.